FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole Co-pack for Early High-Risk Breast Cancer By Ogkologos - October 28, 2024 679 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy of ribociclib with a non-steroidal aromatase inhibitor is based on the results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Scientists reveal how air pollution can cause lung cancer in people... September 10, 2022 What to Know About Coping With Breast Cancer During Pregnancy: An... November 14, 2023 After Being Told a Lump Was Benign, Teenager Learns She Has... August 14, 2021 “Mi corazón siempre dolerá”: Cómo honro a mi mejor amiga de... April 26, 2022 Load more HOT NEWS Being Diagnosed With a Childhood Cancer As an Adult Led Me... Advancing Cancer Prevention: A Conversation with NCI’s Dr. Philip Castle Camonsertib in Patients with Advanced Solid Tumours Harbouring Loss of Function... How Genomic Testing Brought Me a Sense of Control During Metastatic...
